Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the benefit of using the FDA-approved
insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients. The objectives
of this project are to (1) determine if pioglitazone effectively treats insulin resistance in
heart transplant recipients, and (2) to determine whether pioglitazone therapy after heart
transplantation impacts the development or progression of cardiac allograft vasculopathy
(CAV), a form of chronic rejection after heart transplantation.